The INCIPIENT trial establishes CARv3-TEAM-E as a mechanistically sophisticated and biologically active platform for recurrent glioblastoma.
All News
The investigational BCG-containing regimen conferred a weighted anytime CR rate of 69.7% vs 53.4% with nadofaragene firadenovec in this NMIBC group.
Advertisement
Statistical significance was not met with either dose level of fianlimab plus cemiplimab compared with the control arm for patients with advanced melanoma.
Investigators evaluated how subcutaneous isatuximab affected workflow and safety for patients with multiple myeloma.
Disease control was observed in all patients who received JNJ-1900 in part 1 of the phase 2 CONVERGE trial.
Advertisement
Sac-TMT was shown to be the first TROP2 ADC to improve survival vs chemotherapy in patients with endometrial cancer who progressed on chemo- and immunotherapy.
Investigators evaluated how tisagenlecleucel and cilta-cel altered adverse effect timelines for patients treated for hematologic malignancies.
Data from the phase 1/2 SOHO-01 study support the supplemental new drug application for sevabertinib in this NSCLC population.
Based on data from the DESTINY-Breast11 and DESTINY-Breast05 trials, the FDA has approved T-DXd as neoadjuvant and adjuvant treatment for patients with HER2-positive early breast cancer.
Combining zedoresertib with lunresertib yielded activity in patients with CCNE1-altered platinum-resistant ovarian cancer in the phase 1 MYTHIC trial.
107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)
ByAdam M. Brufsky, MD, PhD,François-Clément Bidard,Erica L. Mayer, MD, MPH,Yeon Hee Park,Wolfgang Janni,Cynthia X. Ma, MD, PhD,Massimo Cristofanilli, MD,Giampaolo Bianchini,Kevin Kalinsky, MD, MS,Hiroji Iwata,Stephen Chia,Peter A. Fasching,Zbigniew Nowecki,Javier Pascual,Einav Nili Gal-Yam,Wei-Pang Chung,Seock-Ah Im,Alberto Zambelli,Florence Dalenc,Mafalda Oliveira,Steven Fox,Manuel Selvi Miralles,Christopher Morrow,Cynthia Huang Bartlett,Nicholas C. Turner, MD
SNB-101 monotherapy has previously demonstrated encouraging activity among patients with pretreated small cell lung cancer.
109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR
ByDiana I. Lüftner,Rupert Bartsch,Urs Breitenstein,Christian Jackisch,Volkmar Mueller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Khalil Zaman,Michael Schwitter,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Lidia Perlova-Griff,Rachel Wuerstlein,Timo Schinköthe,Corinne Vannier,Nadia Harbeck, MD, PhD
110 Randomized Phase II Trial Evaluating Three Anti-diarrheal Prophylaxis Strategies in Patients (pts) with HER2+/HR+ Early Breast Cancer (EBC) Treated with Extended Adjuvant Neratinib (Dianer Geicam/2018-06)
ByJ. Gil-Gil,M. Ruíz-Borrego,E. Carrasco,Y. Izarzugaza,C. Martínez-Vila,E. Galve,B. López-Barajas,E. Adrover,T. Silovski,M. Valero-Arbizu,Á. Guerrero-Zotano,S. González-Santiago,M. Echarri,A. Cano-Jiménez,A. Vethencourt-Casado,M. De Laurentis,C. Bueno-Muiño,B. Adamo,R. Andrés,C. Villanueva,F. Rojo,M. Casas,P. Wilson,J. Suissa,V. Adams,M. Martin
Researchers evaluated how a yoga intervention impacted cancer-related fatigue levels among patients undergoing active treatment for solid tumors.
At ONS 2026, Leah R. Yeager, APR, emphasized that improved internal marketing can bridge the knowledge gap and connect patients with free yoga services.
Nurses at Johns Hopkins Nursing utilized a checklist for the chemotherapy gel administration via nephrostomy tube in patients with urothelial cancer.
Sound machines may represent a high-yield, low-effort intervention for improving patient experiences in gynecologic oncology clinics.
Naomi Cazeau, MSN, ANP-BC, AOCNP, discussed how anemia and inflammation drive psychoneurological symptoms in patients with hematologic malignancies.
112 First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial
ByRebecca Dent, MD,Zhimin Shao,Peter Schmid, MD,Javier Cortés, MD,David W. Cescon,Shighira Saji,Kyung Hae Jung,Thomas Bachelot,Shouman Wang,Gul Basaran,Yee Soo Chae,Rofhiwa Mathiba,Shin-Cheh Chen,Agostina Stradella,Nicola Battelli,Naoki Niikura,Kechen Zhao,Petra Vukovic,Michah Maxwell,Tiffany Traina, MD, FASCO
Hua-Jay Cherng, MD, suggested molecular genotyping could replace standard R-CHOP with targeted, less toxic treatments tailored to specific DLBCL subtypes.
Cedars-Sinai investigators transitioned hematology-oncology units to progressive care models to improve safety for patients receiving immunotherapy.
Data from the phase 3 IMvigor011 trial support the approval of adjuvant atezolizumab in this ctDNA MRD-positive MIBC population.
A total of 100 RNs successfully completed the full chemotherapy training program during the 2024 and 2025 evaluation periods.
Results from the phase 3 VOLGA trial demonstrate that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved EFS and OS in MIBC.
Clinician-rated toxicities appear to consistently underreport severity compared with patient-reported outcomes in this lymphoma population.
Advertisement
Advertisement
Trending on CancerNetwork
1
From Conference to Practice: Top 5 Takeaways From EHA 2026
2
Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma
3
Revolutionizing Oncology in the Digital Age: Effects on Health Care Providers
4
Givastomig Earns FDA Fast Track Designation in HER2-Negative Gastric Cancer
5